Physician profile
Jonathan H Fuller
NPI 1013315001
$1,727.91
in general payments reported to CMS, 2019-2025
22 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $268 · 2023: $360 · 2024: $369 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $397.56 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $386.21 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $160.34 | 2022-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $121.32 | 2021-2023 | Freestyle Libre 2 |
| Pfizer INC. | $104.30 | 2024-2025 | |
| Abbvie INC. | $83.99 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.84 | 2021-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $70.56 | 2021-2025 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $66.79 | 2021-2022 | |
| Astellas Pharma US INC | $46.13 | 2023-2024 | Veozah |
| Amgen INC. | $38.70 | 2022-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $27.67 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $22.54 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.52 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.80 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $16.72 | 2023 | Gemtesa |
| Ibsa Pharma INC. | $15.56 | 2024 | Licart, Tirosint |
| Exact Sciences Corporation | $14.20 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.81 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.64 | 2022 | |
| Amarin Pharma, INC. | $11.98 | 2021 | |
| Merck Sharp & Dohme LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.